BMJ partners with European Society for Medical Oncology

July 28, 2015

Global healthcare knowledge provider BMJ has partnered with the European Society for Medical Oncology (ESMO), with the aim of publishing a new open access cancer journal (ESMO Open) from next year, the company has announced.

ESMO has over 10,000 members from over 130 countries, working in cancer care and research, and the new title will be its second official journal after the Annals of Oncology.

ESMO Open represents a first in this field for BMJ, which now has a stable of more than 50 peer reviewed specialist and open access journals in addition to its flagship title The BMJ.

The new title will publish original research covering the full spectrum of cancer treatment, including medical, radiation, and surgical oncology.

And in common with BMJ's other open access titles, ESMO Open will include a wide range of material that isn't always available in more traditional outlets, including study protocols and phase I clinical trials, meta-analyses, small or specialist studies, and interesting case studies.

ESMO Open will also offer a platform for ESMO and other partner societies at national and international level to publish important policy papers for sharing with the cancer care community at large.

The title will operate a fast submission and review process, with continuous publication online, ensuring that up to date high quality research is rapidly available worldwide.
About BMJ:

BMJ is a healthcare knowledge provider that aims to advance healthcare worldwide by sharing knowledge and expertise to improve experiences, outcomes and value. A full list of BMJ products and services is available here:

About ESMO:

ESMO is the leading European professional organisation committed to advancing the specialty of medical oncology and promoting an integrated approach to cancer treatment and care. With its extensive international membership, ESMO represents an ideal platform for oncologists to network, update their knowledge, and improve their practice. For more information, please visit:


Related Clinical Trials Articles from Brightsurf:

Nearly 1 in 5 cancer patients less likely to enroll in clinical trials during pandemic
A significant portion of cancer patients may be less likely to enroll in a clinical trial due to the ongoing coronavirus pandemic.

COVID-19 clinical trials lack diversity
Despite disproportionately higher rates of COVID-19 infection, hospitalization and death among people of color, minority groups are significantly underrepresented in COVID-19 clinical trials.

Why we should trust registered clinical trials
In a time when we have to rely on clinical trials for COVID-19 drugs and vaccines, a new study brings good news about the credibility of registered clinical trials.

Inclusion of children in clinical trials of treatments for COVID-19
This Viewpoint discusses the exclusion of children from coronavirus disease 2019 (COVID-19) clinical trials and why that could harm treatment options for children.

Review evaluates how AI could boost the success of clinical trials
In a review publishing July 17, 2019 in the journal Trends in Pharmacological Sciences, researchers examined how artificial intelligence (AI) could affect drug development in the coming decade.

Kidney patients are neglected in clinical trials
The exclusion of patients with kidney diseases from clinical trials remains an unsolved problem that hinders optimal care of these patients.

Clinical trials beginning for possible preeclampsia treatment
For over 20 years, a team of researchers at Lund University has worked on developing a drug against preeclampsia -- a serious disorder which annually affects around 9 million pregnant women worldwide and is one of the main causes of death in both mothers and unborn babies.

Underenrollment in clinical trials: Patients not the problem
The authors of the study published this month in the Journal of Clinical Oncology investigated why many cancer clinical trials fail to enroll enough patients.

When designing clinical trials for huntington's disease, first ask the experts
Progress in understanding the genetic mutation responsible for Huntington's disease (HD) and at least some molecular underpinnings of the disease has resulted in a new era of clinical testing of potential treatments.

New ALS therapy in clinical trials
New research led by Washington University School of Medicine in St.

Read More: Clinical Trials News and Clinical Trials Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to